Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis
Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. We searched primary original research published through October 2019 in four...
Saved in:
Published in | Anticancer research Vol. 40; no. 5; pp. 2409 - 2418 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Greece
International Institute of Anticancer Research
01.05.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors.
We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase.
Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01).
Oncologists should recognize sex-specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
ISSN: | 0250-7005 1791-7530 1791-7530 |
DOI: | 10.21873/anticanres.14210 |